Clay Siegall leads Seattle Genetics to its Success
Clay Siegall attended the University of Maryland where he graduated with a B.S. in zoology. He later joined George Washington University for his Ph.D. in genetics. Siegall co-established Seattle Genetics in 1998, with the focus on helping cancer patients by developing treatment therapies. The leadership of Clay Siegall at Seattle Genetics has been an instrument, which is evident in how he has led the firm to become sought-after in the industry. Besides, Clay was at the frontline in developing the first FDA-approved antibody-drug conjugate. The drug currently has several approved indications, and it is working on over 20 drugs and other partnerships.
Dr. Clay is of the school of thought that the old-guard of treating cancer, commonly known as systemic chemotherapies is a thing of the past because it is also becoming less effective than before. He believes that there is the need to develop effective targeted drugs. Seattle Genetics, under the leadership of Clay Siegall, has grown from the tiny company it was during its formation to a veritable power player in the medical research field. Clay further points out that he still has great plans with one of them being the list of drugs he is planning to develop. Clay is positioning the company to move to the next level of drug development.
Siegall advises entrepreneurs to learn as much as they can regardless of their age. He adds that entrepreneurs should ensure that they interact with smart people who have been in the industry for several years because they have experience and expertise. The one strategy that has aided in the growth of Seattle Genetics, according to Clay is collaborating with other players in the industry. The ADC’s collaboration has played an integral role in placing new ideas and resources to assist cancer patients. One of the most surprising things about Seattle Genetics is that it made its first profits after ten years of operation. Clay admits that he would have doubts about the company during its initial years; more so when the firm didn’t have enough capital to operate. Also, Seattle Genetics has various ways of making money, including selling its products, partnering with other companies, and licenses.